iCell GABANeurons APP A673V, 01279

Genetic mutations in amyloid precursor protein (APP) have been found to contribute to the early-onset or prevention of Alzheimer’s disease. The A673V variant of APP is associated with early-onset familial Alzheimer’s disease. The contribution of APP A673V to Alzheimer’s pathology is suggested to involve an elevated affinity to β-secretase, increased amyloid-beta (Aβ) production, Aβ aggregation, and neural toxicity.

iCell GABANeurons APP A673V were developed as a cellular model to investigate the genetic predisposition to early-onset Alzheimer’s Disease using a clinically relevant familial APP variant. The heterozygous mutation was engineered into apparently healthy normal induced pluripotent stem cells, followed by differentiation into cortical neurons that exhibit a majority GABAergic phenotype.

Additionally, iCell GABANeurons APP A673T cells with the protective APP variant are ideal for studying genetic protection against Alzheimer’s disease.

Features of iCell GABANeurons A673V:

• Fully differentiated: ≥95% pure neuronal population
• Cell population consists primarily of GABAergic (inhibitory) neurons
• Engineered for heterozygous A673V mutation
• Altered neural activity phenotype compared to isogenic control
• Expresses Tau, APP, and amyloid beta isoforms
• Aβ levels can be modulated by drugs treatments
• Consistent lot-to-lot GABA phenotypes and cell viability
• Isogenic iCell GABANeurons, 01279 are available

View all Alzheimer’s disease cell models here.